{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:03:55Z","timestamp":1771956235657,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Health Labor and Welfare of Japan","award":["Grant-in-Aid for Research on Hepatitis"],"award-info":[{"award-number":["Grant-in-Aid for Research on Hepatitis"]}]},{"name":"Ministry of Education, Science, and Culture of Japan","award":["Scientific Research"],"award-info":[{"award-number":["Scientific Research"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00535-015-1105-9","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T12:30:05Z","timestamp":1438173005000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin"],"prefix":"10.1007","volume":"51","author":[{"given":"Yuki","family":"Tahata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsugiko","family":"Oze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Hijioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Inada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumasa","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Irishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"1105_CR1","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. Hepatol Res. 2014; 44(Suppl S1):59\u201370.","DOI":"10.1111\/hepr.12272"},{"key":"1105_CR2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1586\/14787210.2014.925800","volume":"12","author":"T Takehara","year":"2014","unstructured":"Takehara T. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. Expert Rev Anti Infect Ther. 2014;12:909\u201317.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1105_CR3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403\u201313.","journal-title":"Lancet"},{"key":"1105_CR4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414\u201326.","journal-title":"Lancet"},{"key":"1105_CR5","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669\u201379.","journal-title":"Gastroenterology"},{"key":"1105_CR6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219\u201327.","journal-title":"J Hepatol"},{"key":"1105_CR7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941\u201353.","journal-title":"J Gastroenterol"},{"key":"1105_CR8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/hepr.12375","volume":"45","author":"H Kumada","year":"2015","unstructured":"Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: the CONCERTO-4 study. Hepatol Res. 2015;45:501\u201313.","journal-title":"Hepatol Res"},{"key":"1105_CR9","first-page":"461a","volume":"52","author":"MT Huisman","year":"2010","unstructured":"Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between Tmc435 and hepatic transporters. Hepatology. 2010;52:461a\u20132a.","journal-title":"Hepatology"},{"key":"1105_CR10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289\u201393.","journal-title":"Hepatology"},{"key":"1105_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","volume":"464","author":"J Fellay","year":"2010","unstructured":"Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464:405\u20138.","journal-title":"Nature"},{"key":"1105_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","volume":"139","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181\u20139.","journal-title":"Gastroenterology"},{"key":"1105_CR13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.24068","volume":"53","author":"AJ Thompson","year":"2011","unstructured":"Thompson AJ, Santoro R, Piazzolla V, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2\/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011;53:389\u201395.","journal-title":"Hepatology"},{"key":"1105_CR14","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","volume":"139","author":"H Ochi","year":"2010","unstructured":"Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-A genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139:1190\u20137.","journal-title":"Gastroenterology"},{"key":"1105_CR15","first-page":"1379a","volume":"58","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology. 2013;58:1379a\u201380a.","journal-title":"Hepatology"},{"key":"1105_CR16","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756\u201365.","journal-title":"Lancet"},{"key":"1105_CR17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1872-034X.2010.00711.x","volume":"40","author":"M Ishigami","year":"2010","unstructured":"Ishigami M, Hayashi K, Katano Y, et al. Impact of early elevation of serum bilirubin during treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C. Hepatol Res. 2010;40:963\u201370.","journal-title":"Hepatol Res"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-015-1105-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1105-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:40:16Z","timestamp":1559097616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-015-1105-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s00535-015-1105-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}